Business
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading research in tRNA synthetase biology.
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading research in tRNA synthetase biology. Presentations showcase company’s progress in generating new therapeutics from tRNA synthetase platform. SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada. “As a leader in the field of tRNA biology, we look forward to highlighting some of the recent findings from our platform at AARS 2023,” said Leslie A. Nangle, Ph.D., Vice President, Research at aTyr. “In these presentations we describe the process from concept to clinical proof-of-concept for efzofitimod, our lead tRNA synthetase-derived candidate in development for interstitial lung disease, and how we have applied that same process to identify extracellular targets for two additional tRNA synthetase candidates from our platform. Furthermore, we present exciting findings that solidify a connection between patients with certain genetic conditions and lower circulating levels of the tRNA synthetase HARS, which forms the active portion of efzofitimod. As these patients exhibit dysregulated respiratory immune responses, this data provides rationale for a link between human extracellular HARS deficiency and diseases with respiratory symptoms.” Extracellular tRNA synthetases represent a class of proteins that may play important roles in regulating cellular responses to certain disease states, in particular, cellular stress and imbalances in tissue homeostasis. aTyr is focused on elucidating novel pathways mediated through extracellular tRNA synthetases and creating new biologics to modulate these pathways by developing protein therapies based on extracellular tRNA synthetase fragments. Details of the presentations appear below. The posters will be available on the aTyr website once presented. Title: Clinical Proof-of-Concept for a Novel Therapeutic Based on Histidyl-tRNA Synthetase for Treatment of Interstitial Lung Di...